fungerer som normalt hos meg
Ser ok ut for meg. Hva er problemet?
Ehh… nå fungerer det her også 
Tror bare serveren har hatt litt problemer i dag.
Er der 2 eller 3 read-outs tilbage her i første halvår?
Selskapet selv guider 6 interim read-outs til ASCO18.
BerGenBio melder om ferdig rekruttering av første del i NSCLC studiet. Her er det snakk om 22 pasienter som er innrullert. Studien er en kombinasjon av Keytruda og bemcentinib. Analyse av disse pasientene vil bestemme om studiet fortsetter eller ikke: http://www.bergenbio.com/bergenbio-completes-recruitment-into-first-stage-of-phase-ii-nsclc-trial-with-selective-axl-inhibitor-bemcentinib-combined-with-keytruda/
Når kan man forvente publisering av readout på denne!?
På ASCO?
De sier at selv at de skal komme med noe data der:
Men de skal på World Lung i H2 så blir kanskje mer data der.
1 Like
Ser at de også har fått en ny hjemmeside! Nå vet vi hvorfor den har vært litt “av og på” i det siste.
Ny hjemmeside feires med 10% oppgang. Dette bør de gjøre oftere!
De nye sidene for investorer synes ihvertfall jeg var mildt sakt mega bra.
http://www.netfonds.no/quotes/release.php?id=20180413.OBI.20180413S9
Boom!
Bergen, Norway, 13 April 2018 - BerGenBio ASA (OSE: BGBIO) (“BerGenBio” or the
"Company") a clinical-stage biopharmaceutical company developing novel,
selective AXL kinase inhibitors as a potential cornerstone of combination cancer
therapy in NSCLC, AML/MDS, TNBC and
melanoma (https://www.bergenbio.com/pipeline/), announces today that it has
raised NOK 187.5 million (USD24m) in gross proceeds through a private placement
of 4,629,246 new shares (the “Private Placement”).
The Private Placement was priced after close of trading on Oslo Stock Exchange
yesterday at a subscription price of NOK 40.50 per share. The price was
determined through an oversubscribed book-building process primarily directed
towards sophisticated institutional investors in the United States specialising
in the biotechnology sector.
On 9 March 2018, at an extraordinary general meeting of BerGenBio ASA,
shareholders granted the Company’s board of directors (the “Board”) an
authorisation to increase the share capital. The purpose of the authorisation
was to permit the issue of new shares in the Company to strengthen the CompanyŽs
equity and to increase the liquidity and/or to broaden the Company’s shareholder
base with domestic and international investors that may include healthcare
specialist investors. At a board meeting held on 13 April 2018 the Board, based
on the above-mentioned authorisation, resolved to increase the share capital of
the Company as part of the Private Placement.
Guggenheim Securities and Arctic Securities acted as joint-lead placement agents
and bookrunners (the “Placement Agents”) in connection with the Private
Placement. Advokatfirmaet Thommessen and Baker McKenzie LLP acted as counsels to
the Company and Advokatfirmaet Selmer and White & Case LLP acted as counsels to
the Placement Agents.
BerGenBio intends to use the net proceeds of the Private Placement to fund the
ongoing clinical development of pipeline candidates, strengthen working capital
and general corporate purposes.
Completion of the Private Placement is expected to take place on 17 April 2018,
subject to the condition that the placement agent agreement between the Company
and the Placement Agents is not terminated. After registration of the new share
capital, the total share capital will be NOK 5,471,144.60 divided into
54,711,446 shares, each with a nominal value of NOK 0.10.
The Board has assessed the Private Placement in light of the equal treatment
requirement, balanced the considerations that speak for and against carrying out
the Private Placement and concluded that the waiver of the preferential rights
inherent in a private placement was considered necessary in the interest of time
and successful completion in the common interest of the Company and its
shareholders, as well as being in accordance with the stated purpose of the
authorisation from the extraordinary general meeting to the Board to increase
the share capital.
- END -
1 Like
Mon tro om den åpner 10% ned da. Men positivt at de får langsiktigve penger til en god kurs!
13/04-2018 08:00:17: (BGBIO) Promising pre-clinical data supporting BerGenBio’s pipeline to be published and presented at upcoming leading conferences
· Bemcentinib active in pre-clinical models of IPF and NASH
· IPF and cirrhotic NASH patients with aggressive disease identified by AXL
blood based biomarker
· BGB601 (partnered AXL ADC drug candidate) anti tumour pre-clinical data to
be presented at AACR.
Bergen, Norway, 13 April 2018 - BerGenBio ASA (OSE: BGBIO) announces that
promising pre-clinical data demonstrating that selective AXL inhibition
counteracts the progression of aggressive fibrosis in the lung and liver has
been published in the international peer-reviewed journal American Journal of
Respiratory and Critical Care Medicine (AJRCCM, (1)) and accepted for
presentation at the 53rd annual meeting of the European Association for the
Study of the Liver (EASL), respectively.
Additionally, pre-clinical data of BerGenBio’s out-licensed AXL ADC candidate
BGB601 has been accepted for presentation at the American Association for Cancer
Research (AACR) Annual Meeting 2018.
The details of the publications are as follows:
Potential of selective AXL inhibition as a mechanism for treating the
progressive, rare, and frequently fatal lung disease idiopathic pulmonary
fibrosis (IPF):
Milena Espindola and colleagues from Cedars-Sinai in Los Angeles, CA, published
evidence in the American Journal of Respiratory and Critical Care Medicine
(AJRCCM) that AXL receptor expression is significantly elevated in patient
cells, tissues and models of IPF. Consistent with the pathological role of AXL
in fibrosis, selective inhibition of AXL using bemcentinib (BGB324) impacted IPF
fibroblast functions and the development of fibrosis in pre-clinical models of
IPF. The data also show a clear distinction in AXL levels between fast and slow
progressing IPF patients, highlighting the potential of using AXL levels as a
biomarker to (i) identify patients with a poor prognosis and who may respond to
treatment with an AXL inhibitor, and (ii) enrich patient populations in future
clinical trials.
The article in press is entitled: “Targeting of TAM Receptors Ameliorates
Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis” and can be accessed at the
AJRCCM’s website - click
here (http://www.atsjournals.org/doi/abs/10.1164/rccm.201707-1519OC).
Potential of selective AXL inhibition for treating advanced form of non
-alcoholic steatohepatitis (NASH)
Anna Tutusaus et al. will be presenting a poster on AXL targeting in NASH
entitled “AXL increase in NASH patients and anti-fibrotic efficacy of AXL
inhibition in experimental NASH” (abstract: FRI-074) at the European Association
for the Study of the Liver (EASL) Annual Meeting in Paris, France, on Friday 13
April between 9 and 17:00 CET.
The abstract is available online - click here (https://program.m
-anage.com/ProgramSearch/?eventName=ilc2018&language=en
-GB&searchString=axl&pProgramGrade=Scientific).
Pre-clinical data in models of aggressive, AXL expressing, tumours supporting
clinical development of AXL ADC BGB601 (ADCT-601)
Lorenzo Zammarchi et al. will be presenting a poster on the in vitro and in vivo
anti-tumour activity of BGB601 (ADCT-601) in human cancer cell lines and animal
models as well as data on its safety and tolerability entitled “Preclinical
activity of ADCT-601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody
-drug conjugate (ADC) targeting AXL-expressing tumors” (abstract: 2792A) at the
American Association of Cancer Research (AACR) Annual Meeting in Chicago, IL, on
Monday 16 April between 13:00 and 17:00 CDT.
The abstract is available online at the AACR Annual Meeting website - click
here (http://www.abstractsonline.com/pp8/#!/4562/presentation/9909).
Richard Godfrey, CEO of BerGenBio commented: “This patient data and pre-clinical
findings in IPF and cirrhotic NASH are very compelling and suggest that
selective AXL inhibition may have potential as a new approach to treating life
-threatening fibrotic diseases. While our focus remains clearly on completing
our phase II clinical programme with bemcentinib and to establish proof of
concept for its role as a cornerstone of cancer therapy, we are intrigued by the
possibility of therapeutic benefit from our AXL inhibitors in fibrotic diseases.
We will continue to support this research and look forward to integrating it
into our pipeline development strategies. Furthermore, we are encouraged by pre
-clinical data supporting the advancement of BGB601, our out-licensed AXL ADC
drug candidate, towards the clinic.”
-End-
Dette må jo bli himmel eller helvete da…
“Hvordan klarte du å selge deg ut for å trade på tirsdag???”
Skjønner ikke helt hvordan dette skal bli helvete. Det må i tilfelle bli for dem som har solgt seg ut de siste dagene. Men dersom man følger med på BGBIO så skjønner jeg heller ikke hvorfor man har solgt seg ut like før AACR kommende uke. Men i aksjemarkedet er hver sin egen lykkes smed og man ligger som man reder.
Ha en god dag.
Jeg så en rolig periode og hadde en annen aksje jeg dro inn en del på og man har bare så meget penger at avse. Skulle egentlig inn i går, men hadde ikke tid til å følge med på markedet etter 14
Åhåhåhåhå
"Potential of selective AXL inhibition for treating advanced form of non-alcoholic steatohepatitis"
Ikke-alkoholisk fettleversykdom!
Dette betyr at potensielt alle som er kraftig overvektige skal ha behandling med bemcentinib.
1 Like
Er ikke lite marked det nei… IPF pluss NASH. Blir spennende å se hvor lang tid det tar før vi evt. ser noe i fase I.
PS: Den dagen de får disse programmene inn i klinisk testing, og hvis de samtidig har kreftprogrammene kjørende, så snakker vi en heftig re-prising av selskapet.
1 Like
Så da er vel selskapet mildt sagt velfinansiert.